Abstract
In light of the finding that certain serotonergic agents are not as selective as previously considered, the functional/clinical significance of various populations of 5-HT binding sites is reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Norman, A.W., Battaglia, G., Morrow, L. and Creese, I. (1985) ‘[3H] WB-4101 labels SI serotonin receptors in rat cerebral cortex’, Eur. J. Pharmacol. 106, 461–462.
Gross, G., Hanft, G. and Kolassa, N.’Urapadil and some analogs with hypotensive properties show high affinities for 5-hydroxytryptamine (5-HT) binding sites of the 5-HT1A subtype and for al-adrenoceptor binding sites’, (1987) Naunyn-Schmiedebergs Arch. Pharmacol. 336, 597–601.
Glennon, R.A. (1989) ‘Central serotonin receptors’, in M. Williams, R.A. Glennon and P.B.M.W.M. Timmermans (eds.) Receptor Pharmacology and Function, Marcel Dekker, New York, pp. 257–292.
Kilpatrick, G.J., Jones, B.J. and Tyers, M.B. (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding’, Nature 330, 746–748.
Leysen, J.E., Awouters, F., Kennis, L., Laduron, P.M., Vandenberk, J. and Janssen, P.A.J. (1981) ‘Receptor binding profile of R 41 468 a novel antagonist at 5-HT2 receptors’, Life Sci. 28, 1015–1022.
Battaglia, G., Shannon, M., Borgundvaag, B. and Titeler, M. (1984) J. Receptor Res. 4, 713–720.
Hoyer, D., Vos, P., Closse, A., Palacios, J.M., Engel, G. and Davies, H. (1987) 13H-Ketanserin labels both 5-HT2 sites and c*2- adrenergic sites in human brain cortex’, J. Cardiovasc. Pharmacol. 10 (Suppl 3 ), S48–S50.
Leysen, J.E., Eens, A., Gommeren, W., van Gompel, P., Wynants, J. and Janssen, P.A.J. (1988) ‘Identification of nonserotonergic [3H]- ketanserin binding sites associated with nerve terminals in rat brain and with platelets; Relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs’, J. Pharmacol. Exp. Ther. 244, 310–322.
Darchen, F., Scherman, D., Laduron, P.M. and Henry, J.-P. (1988) ‘Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles’, Mol. Pharmacol. 33, 672–677.
O’Dell, S.J. and Marshall, J.F. (1988) ‘Autoradiographic localization of distinct serotonergic and nonserotonergic [3H]ketanserin binding sites’, Soc. Neurosci. Abstr. 14, 778.
Herrick-Davis, K., Titeler, M., Leonhardt, S., Struble, R. and Price, D. (1988) ‘Serotonin 5-HT1D receptors in human prefrontal cortex and caudate: Interaction with a GTP binding protein’, J. Neurochem. 51, 1906–1912.
Peroutka, S.J. and Hamik, A. (1988) [3H]Quipazine labels 5-HT3 recognition sites in rat cortical membranes’, Eur. J. Pharmacol. 148, 297–299.
Hoyer, D., Engel, G. and Kalkman, H.O. (1985) ‘Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: Radioligand binding studies with [3H]5-HT, [3H]8-OH DPAT, (-)[1251]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin’, Eur. J. Pharmacol. 118, 13–23.
Waeber, C., Schoeffter, P., Palacios, J.M. and Hoyer, D. (1988) ‘Molecular pharmacology of 5-HT1D recognition sites: Radioligand binding studies in human, pig and calf brain membranes’, Naunyn- Schmiedebergs Arch. Pharmacol. 337, 595–601.
Glennon, R.A., Ismaiel, A.M., McCarthy, B. and Peroutka, S.J. (1989) ‘Binding of arylpiperazines to 5-HT3 5-hydroxytryptamine binding sites: Results of a structure-affinity study’, Eur. J. Pharmacol, (submitted).
Cohen, M.L. and Fuller, R.W. (1983) ‘Antagonism of vascular serotonin receptors by m-chlorophenylpiperazine and m-trifluoromethylphe- nylpiperazine in rats’, Life Sci. 32, 711–718.
Glennon, R.A., Slusher, R.M., Lyon, R.A., Titeler, M. and McKenney, J.D. (1986) ‘5-HT1 and 5-HT2 binding characteristics of some quipa- zine analogues’, J. Med. Chem. 29, 2375–2380.
Sanders-Bush, E. and Conn, P.J. (1986) ‘Effector systems coupled to serotonin receptors in brain: Serotonin stimulated phosphoinositide hydrolysis’, Psychopharmacol. Bull. 22, 829–836.
Britt, S.G., Gonias, S.L., Sanders, J.M. and Vandenberg, S. (1988) ‘Agonist and antagonist activities of arylpiperazines at platelet serotonin2 receptors’, J. Pharmacol. Exp. Ther. 247, 965–970.
Simansky, K.J. and Schechter, L.E. (1988) ‘Properties of some 1- arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents’, J. Pharmacol. Exp. Ther. 247, 1073–1081.
Kennett, G.A. and Curzon, G. (1988) ‘Evidence that the hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors’, Psychopharmacology 96, 93–100.
Titeler, M., Lyon, R.A. and Glennon, R.A. (1988) ‘Radioligand binding evidence implicates the brain 5-HT2 receptors as a site of action for LSD and phenylisopropylamine hallucinogens’, Psychopharmacology 94, 213–216.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Kluwer Academic Publishers
About this chapter
Cite this chapter
Glennon, R.A. (1990). Functional/Clinical Significance of 5-Hydroxytryptamine Binding Sites. In: Paoletti, R., Vanhoutte, P.M., Brunello, N., Maggi, F.M. (eds) Serotonin. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1912-9_33
Download citation
DOI: https://doi.org/10.1007/978-94-009-1912-9_33
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7353-0
Online ISBN: 978-94-009-1912-9
eBook Packages: Springer Book Archive